AJR Your Link to CME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CLEMENTS, J. P.
Right arrow Articles by GOODWIN, D. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by CLEMENTS, J. P.
Right arrow Articles by GOODWIN, D. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
American Journal of Roentgenology, Vol 104, 139-144, Copyright © 1968 by American Roentgen Ray Society

INDIUM 113m DIETHYLTRIAMINOPENTACETIC ACID (DTPA): A NEW RADIOPHARMACEUTICAL FOR BRAIN SCANNING

JOHN P. CLEMENTS 1, H. N. WAGNER JR. 1, H. S. STERN 1, and DAVID A. GOODWIN 1

1 From the Division of Nuclear Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland

We have developed and evaluated a new

[See figure in the PDF file]

radiopharmaceutical, indium 113m diethyltriaminopentacetic acid (DTPA) as a brain scanning agent. In113 which has a half-life of 1.7 hours is obtained in ionic, carrierfree form by elution of a Sn113 (tin) generator system.

The chelate In113m DTPA can be perpared simply and rapidly. Satisfactory

[See table in the PDF file]

tumor: brain concentration ratios were found in experimental tumors in mice and in brain tumors in man. Over 400 brain scannings have been performed with satisfactory results and without untoward effects. In 87 patients, brain scannings with both Tc99m pertechnetate and In113m DTPA were carried out. The images were essentially the same with both agents.

In113m DTPA was found to be comparable to Tc99m pertechnetate in the detection and characterization of intracranial lesions. The long half-life of 118 days of the parent Sn113 is an advantage since replenishment is required only at 6 month intervals rather than weekly as in the case of the Mo99/Tc99m generator.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1968 by the American Roentgen Ray Society.